Guidance To Cut Diabetes Drug CV Risk Gets First Test With Pending NDAs

FDA’s flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late-stage development.